Kahn Nighat N, Sinha Asru K, Spungen Ann M, Bauman William A
Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Am J Hematol. 2006 Feb;81(2):95-100. doi: 10.1002/ajh.20532.
This study evaluated the short-term effects of oxandrolone, an anabolic androgenic synthetic steroid, on blood coagulation and the hemostatic/fibrinolytic system in healthy individuals. Subjects (n = 14) were administered oxandrolone (10 mg twice daily) for 14 days. Blood was obtained on days 0, 1, 3, 7, 9, 14, and then at day 42 (28 days after discontinuation of the drug). Samples were analyzed for the plasma plasminogen, plasminogen activator inhibitor (PAI-1), fibrinogen, and coagulation factors (II, V, VII, VIII, and X). After 7 days of administration of oxandrolone, the plasma plasminogen level significantly increased [100% +/- 21% to 174% +/- 21% (P < 0.0001)]. PAI-1 was significantly decreased at day 3 [16 +/- 9 to 7 +/- 4 mg/dL (P < 0.01)]. Coagulation factors II and V significantly increased at day 14 [88 +/- 15 to 122 +/- 11 (P < 0.005) and 105 +/- 21 to 179 +/- 36% (P < 0.0001)], respectively. Factor VII level decreased by day 3 [91% +/- 26% to 83% +/- 18%, NS], but after 14 days factor VII level returned to baseline (91% +/- 26% to 93% +/- 19%, NS). The increase of factor VIII level was not significant (111% +/- 64% to 125% +/- 55%, NS). Factor X increased steadily over 14 days of drug treatment [96% +/- 11% to 107% +/- 25%, NS] and after discontinuation, decreased and returned to baseline by day 42 [107% +/- 25% to 89% +/- 25%, NS]. Fibrinogen decreased by 22% +/- 12%, (NS). Administration of oxandrolone, to healthy young men was associated with a significant increase in select blood coagulation factors and plasminogen. These changes create a state of potential hypercoagulability that appears to be counterbalanced by increased fibrinolytic activity to maintain homeostasis.
本研究评估了合成代谢雄激素类固醇奥氮龙对健康个体血液凝固及止血/纤维蛋白溶解系统的短期影响。受试者(n = 14)接受奥氮龙(每日两次,每次10 mg)治疗14天。在第0、1、3、7、9、14天采血,然后在第42天(停药28天后)采血。对样本进行血浆纤溶酶原、纤溶酶原激活物抑制剂(PAI - 1)、纤维蛋白原及凝血因子(II、V、VII、VIII和X)分析。奥氮龙给药7天后,血浆纤溶酶原水平显著升高[从100%±21%升至174%±21%(P < 0.0001)]。PAI - 1在第3天显著降低[从16±9降至7±4 mg/dL(P < 0.01)]。凝血因子II和V在第14天分别显著升高[从88±15升至122±11(P < 0.005)和从105±21升至179±36%(P < 0.0001)]。因子VII水平在第3天下降[从91%±26%降至83%±18%,无统计学意义],但14天后因子VII水平恢复至基线(从91%±26%升至93%±19%,无统计学意义)。因子VIII水平升高不显著(从111%±64%升至125%±55%,无统计学意义)。因子X在药物治疗的14天内稳步升高[从96%±11%升至107%±25%,无统计学意义],停药后下降,至第42天恢复至基线[从107%±25%降至89%±25%,无统计学意义]。纤维蛋白原下降22%±12%(无统计学意义)。对健康年轻男性给予奥氮龙与特定凝血因子和纤溶酶原的显著增加有关。这些变化产生了潜在的高凝状态,而这种状态似乎通过增加纤维蛋白溶解活性来维持体内平衡而得到平衡。